Lalla Rajesh V, Sonis Stephen T, Peterson Douglas E
Division of Oral Medicine, Department of Oral Health and Diagnostic Sciences, University of Connecticut Health Center MC 1605, 263 Farmington Avenue, Farmington, CT 06030, USA.
Dent Clin North Am. 2008 Jan;52(1):61-77, viii. doi: 10.1016/j.cden.2007.10.002.
Oral mucositis is a clinically important and sometimes dose-limiting complication of cancer therapy. Mucositis lesions can be painful, affect nutrition and quality of life, and have a significant economic impact. The pathogenesis of oral mucositis is multifactorial and complex. This review discusses the morbidity, economic impact, pathogenesis and clinical course of mucositis. Current clinical management of oral mucositis is largely focused on palliative measures such as pain management, nutritional support and maintenance of good oral hygiene. However, several promising therapeutic agents are in various stages of clinical development for the management of oral mucositis. These agents are discussed in the context of recently updated evidence-based clinical management guidelines.
口腔黏膜炎是癌症治疗中一种具有临床重要性且有时会限制剂量的并发症。黏膜炎病变会引起疼痛,影响营养状况和生活质量,并产生重大经济影响。口腔黏膜炎的发病机制是多因素且复杂的。本综述讨论了黏膜炎的发病率、经济影响、发病机制和临床病程。目前口腔黏膜炎的临床管理主要集中在姑息治疗措施,如疼痛管理、营养支持和保持良好的口腔卫生。然而,有几种有前景的治疗药物正处于治疗口腔黏膜炎的不同临床开发阶段。这些药物在最近更新的循证临床管理指南的背景下进行了讨论。